Formulation and Optimization of Chitosan-Based Flurbiprofen Nanoparticles for Ocular Delivery: A Design of Experiments Approach.

IF 1.8 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS
Assay and drug development technologies Pub Date : 2026-07-01 Epub Date: 2026-03-14 DOI:10.1177/1540658X261429252
Emine Dilek Özyılmaz
{"title":"Formulation and Optimization of Chitosan-Based Flurbiprofen Nanoparticles for Ocular Delivery: A Design of Experiments Approach.","authors":"Emine Dilek Özyılmaz","doi":"10.1177/1540658X261429252","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to design and develop flurbiprofen-loaded chitosan nanoparticles for ophthalmic drug delivery, with the objectives of enhancing formulation stability, sustaining drug release, and improving patient comfort. This study introduces an optimized chitosan-based nanoparticle system for ocular delivery of flurbiprofen, achieving high encapsulation efficiency, physiological compatibility, and sustained release for 20 h. The findings demonstrate a practical, patient-friendly approach that enhances drug bioavailability and stability compared with conventional eye drops. Flurbiprofen-loaded nanoparticles were prepared using gelation and optimized through a Box-Behnken design. The influence of formulation variables (0.1%-0.3% w/v chitosan concentration, 0.2-0.6 mL/min dropping rate, and 500-900 rpm mixing speed) was assessed. The optimized nanoparticles were evaluated for particle size, polydispersity index (PDI), zeta potential, pH, osmolarity, and entrapment efficiency (%). The optimized formulation was achieved at 0.2% (w/v) chitosan concentration, a dropping rate of 0.4 mL/min, and a mixing speed of 700 rpm. The nanoparticles exhibited a particle size of 110.0 ± 2.20 nm, PDI of 0.347 ± 0.03, and zeta potential of + 15.4 ± 3.8 mV. The entrapment efficiency was 80.89%. The formulation was adjusted to physiological conditions (pH 6.7, osmolarity 300 mOsm/kg). <i>In vitro</i> studies showed a controlled release of flurbiprofen over 20 h. The optimized chitosan-based nanoparticle system demonstrated favorable physicochemical stability, high encapsulation efficiency, and sustained release of flurbiprofen. Compared with conventional ocular formulations, this structured nanoparticle delivery system offers superior drug retention and extended therapeutic action.</p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"444-454"},"PeriodicalIF":1.8000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Assay and drug development technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1540658X261429252","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to design and develop flurbiprofen-loaded chitosan nanoparticles for ophthalmic drug delivery, with the objectives of enhancing formulation stability, sustaining drug release, and improving patient comfort. This study introduces an optimized chitosan-based nanoparticle system for ocular delivery of flurbiprofen, achieving high encapsulation efficiency, physiological compatibility, and sustained release for 20 h. The findings demonstrate a practical, patient-friendly approach that enhances drug bioavailability and stability compared with conventional eye drops. Flurbiprofen-loaded nanoparticles were prepared using gelation and optimized through a Box-Behnken design. The influence of formulation variables (0.1%-0.3% w/v chitosan concentration, 0.2-0.6 mL/min dropping rate, and 500-900 rpm mixing speed) was assessed. The optimized nanoparticles were evaluated for particle size, polydispersity index (PDI), zeta potential, pH, osmolarity, and entrapment efficiency (%). The optimized formulation was achieved at 0.2% (w/v) chitosan concentration, a dropping rate of 0.4 mL/min, and a mixing speed of 700 rpm. The nanoparticles exhibited a particle size of 110.0 ± 2.20 nm, PDI of 0.347 ± 0.03, and zeta potential of + 15.4 ± 3.8 mV. The entrapment efficiency was 80.89%. The formulation was adjusted to physiological conditions (pH 6.7, osmolarity 300 mOsm/kg). In vitro studies showed a controlled release of flurbiprofen over 20 h. The optimized chitosan-based nanoparticle system demonstrated favorable physicochemical stability, high encapsulation efficiency, and sustained release of flurbiprofen. Compared with conventional ocular formulations, this structured nanoparticle delivery system offers superior drug retention and extended therapeutic action.

壳聚糖基氟比洛芬纳米颗粒眼部给药的配方与优化:实验设计方法。
本研究旨在设计和制备负载氟比洛芬的壳聚糖纳米颗粒用于眼科给药,以提高处方稳定性、药物缓释和改善患者舒适度。本研究介绍了一种优化的壳聚糖纳米颗粒系统,用于氟比洛芬的眼部递送,具有高包封效率、生理相容性和20小时的缓释。研究结果表明,与传统滴眼液相比,这是一种实用的、对患者友好的方法,可提高药物的生物利用度和稳定性。采用凝胶法制备了负载氟比洛芬的纳米颗粒,并通过Box-Behnken设计进行了优化。考察了配方变量(0.1% ~ 0.3% w/v壳聚糖浓度、0.2 ~ 0.6 mL/min滴药速率、500 ~ 900 rpm混合速度)的影响。对优化后的纳米颗粒进行粒径、多分散性指数(PDI)、zeta电位、pH、渗透压和包封效率(%)的评价。最佳配方为壳聚糖浓度为0.2% (w/v),滴速为0.4 mL/min,搅拌速度为700 rpm。纳米颗粒粒径为110.0±2.20 nm, PDI为0.347±0.03,zeta电位为+ 15.4±3.8 mV。捕集效率为80.89%。将配方调整到生理条件(pH 6.7,渗透压300 mOsm/kg)。体外实验表明,氟比洛芬在20 h内缓释。优化后的壳聚糖纳米颗粒体系具有良好的理化稳定性、高的包封效率和氟比洛芬的缓释作用。与传统的眼部配方相比,这种结构纳米颗粒输送系统提供了优越的药物保留和延长的治疗作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Assay and drug development technologies
Assay and drug development technologies 医学-生化研究方法
CiteScore
3.60
自引率
0.00%
发文量
33
审稿时长
>12 weeks
期刊介绍: ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This reputable peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application. ASSAY and Drug Development Technologies coverage includes: -Assay design, target development, and high-throughput technologies- Hit to Lead optimization and medicinal chemistry through preclinical candidate selection- Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis- Approaches to assays configured for gene families, inherited, and infectious diseases- Assays and strategies for adapting model organisms to drug discovery- The use of stem cells as models of disease- Translation of phenotypic outputs to target identification- Exploration and mechanistic studies of the technical basis for assay and screening artifacts
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书